Madison, Wisconsin, August 25, 2015 - HealthMyne, an imaging informatics company, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA). The new imaging informatics platform is designed to streamline clinical decision support and integrate with enterprise PACS and vendor-neutral archives using industry-standard formats.
HealthMyne’s team has leveraged their previous clinical and commercial success within image management to create this innovative software foundation. The new system directly aligns with the ACR (American College of Radiology) Imaging 3.0 initiative which addresses the radiologist’s emerging role as diagnostic imaging consultant to all clinicians, both before and after the imaging encounter.
"Having a strong diagnostic imaging platform cleared by the FDA is the first step in our vision of bringing imaging informatics to mainstream healthcare, said Praveen Sinha, CEO of HealthMyne. "Significant achievements are being realized elsewhere through clinical data aggregation and analysis, yet imaging has gone largely untapped. As an example, the potential impact of streamlined patient cohort comparison on personalized medicine is truly exciting."
According to a new report by whatech.com, the global healthcare IT analytics market is expected to grow at a compound annual growth rate (CAGR) of 26.5 percent and reach more than $18 billion by 2020.
HealthMyne will be exhibiting (North Building, Hall B, Booth 8310) at the Annual Meeting of the Radiological Society of North America in Chicago from November 29 to December 4, 2015.
For HealthMyne Contact:
Del Coufal
del.coufal@healthmyne.com
About HealthMyne:
HealthMyne is an imaging informatics company dedicated to transforming patient care by enabling image data mining within the clinical workflow. Built on an FDA-cleared diagnostic platform, HealthMyne tools will increase radiologist efficiency by automating both data capture and structured reports. HealthMyne software will combine imaging and electronic health record data to provide stakeholders with integrated patient progression timelines as well as analytics for comparing individual patients to specific populations. Academic and industrial researchers can use HealthMyne analytic tools to explore quantitative imaging biomarkers, including radiomic signature development, as well as supporting improved clinical trials of innovative therapies.
